Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Optimizing LDL-C lowering with statins.

James M McKenney¹

¹Virginia Commonwealth University and National Clinical Research, 2809 Emerywood Parkway, Suite 140, Richmond, VA 23294, USA. jmckenney@ncrinc.net

American Journal of Therapeutics

|January 6, 2004

Summary

Choosing a more potent statin helps more patients reach their cholesterol goals. This approach is often better than adding other drugs due to cost, safety, and effectiveness.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial.

Journal of clinical lipidology·2021

Same author

Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial.

Journal of clinical lipidology·2020

Same author

Alirocumab in high-risk patients: Observations from the open-label expanded use program.

Journal of clinical lipidology·2018

Same author

Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II).

The American journal of cardiology·2017

Same author

Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance.

Journal of clinical lipidology·2016

Same author

Effect of ETC-1002 on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients Receiving Statin Therapy.

The American journal of cardiology·2016

Area of Science:

Cardiovascular Medicine
Pharmacology

Background:

Statins effectively lower low-density lipoprotein cholesterol (LDL-C) and reduce coronary heart disease risk.
Many patients on statin therapy do not achieve their LDL-C treatment goals in clinical practice.
Dose titration is often necessary but limited by cost, safety concerns, and monitoring requirements.

Purpose of the Study:

To evaluate strategies for improving LDL-C goal attainment in patients receiving statin therapy.
To compare the effectiveness of using more efficacious statins versus adding other lipid-lowering drugs.

Main Methods:

Review of clinical studies on statin efficacy and patient outcomes.
Analysis of factors influencing statin dose titration in clinical practice.
Comparison of treatment approaches including statin selection and add-on therapies.

Main Results:

More efficacious statins enable a greater number of patients to achieve LDL-C goals.
The majority of patients can reach therapeutic targets with starting doses of potent statins.
Combination therapy with other lipid-lowering drugs is less preferred than using a more effective statin.

Conclusions:

Selecting a statin with higher LDL-C lowering capacity is a preferred strategy for achieving treatment goals.
Using more potent statins offers advantages in terms of cost, safety, effectiveness, and simplicity compared to combination therapy.

Related Experiment Videos